[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626931":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":108,"collaborators":10,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":10,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":10,"enrollmentInfo":120,"targetDuration":10,"studyType":123,"phases":10,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Upadacitinib Plus Vedolizumab",null,"Patients received oral upadacitinib 45 mg once daily for 8 weeks and intravenous vedolizumab 300 mg at weeks 0, 2, and 6 during induction.",[13,14],"Drug: Upadacitinib","Drug: Vedolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Upadacitinib Monotherapy","Patients received oral upadacitinib 45 mg once daily for 8 weeks without concomitant vedolizumab or another advanced therapy.",[13],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Upadacitinib","Oral Upadacitinib 45mg\u002Fd for 8 weeks in the induction therapy.",[16,9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Vedolizumab","Vedolizumab 300mg intravenously on weeks 0, 2, 6.",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Jiayin Yao","CONTACT","13826462890","yjyin@mail2.sysu.edu.cn",[36,54,64,74,86,95],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The First People's Hospital of Foshan","RECRUITING","Foshan","Guangdong","510260","China","CN",{"type":45,"coordinates":46},"Point",[47,48],113.13148,23.02677,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":10,"phoneExt":10,"email":53},"Peizhu Su, MD","supeizhu1986@163.com",{"facility":55,"status":38,"city":39,"state":40,"zip":56,"country":42,"countryCode":43,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Foshan Fosun Chancheng Hospital, Foshan","528000",{"type":45,"coordinates":58},[47,48],{"lat":48,"lon":47},[61],{"name":62,"role":32,"phone":10,"phoneExt":10,"email":63},"Ji Wu, MD","13929190198@139.com",{"facility":65,"status":38,"city":39,"state":40,"zip":66,"country":42,"countryCode":43,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"The Sixth Affiliated Hospital, South China University of Technology City: Foshan","528200",{"type":45,"coordinates":68},[47,48],{"lat":48,"lon":47},[71],{"name":72,"role":32,"phone":10,"phoneExt":10,"email":73},"Huangwei Chen, MD","chw1364@163.com",{"facility":75,"status":38,"city":76,"state":40,"zip":77,"country":42,"countryCode":43,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"the Sixth Affiliated Hospital of Sun Yat-sen University","Guangzhou","501655",{"type":45,"coordinates":79},[80,81],113.25,23.11667,{"lat":81,"lon":80},[84],{"name":85,"role":32,"phone":10,"phoneExt":10,"email":34},"Jiayin Yao, MD",{"facility":87,"status":38,"city":76,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"The Second Affiliated Hospital of Guangzhou Medical University",{"type":45,"coordinates":89},[80,81],{"lat":81,"lon":80},[92],{"name":93,"role":32,"phone":10,"phoneExt":10,"email":94},"Tingting Xie, MD","jianning.22@163.com",{"facility":96,"status":38,"city":97,"state":40,"zip":98,"country":42,"countryCode":43,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"the Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Bao'an District)","Shenzhen","518000",{"type":45,"coordinates":100},[101,102],114.0683,22.54554,{"lat":102,"lon":101},[105],{"name":106,"role":32,"phone":10,"phoneExt":10,"email":107},"Xiaoyu Liu, MD","LXY-631@126.com",{"type":109,"investigatorFullName":31,"investigatorTitle":110,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100626931","real-world-effectiveness-and-safety-of-upadacitinib-plus-vedolizumab-vs-upadacitinib-monotherapy-during-induction-in-moderate-to-severe-ulcerative-colitis-100626931",false,"NCT07442045","Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis","Real-World Comparative Effectiveness and Safety of Upadacitinib Plus Vedolizumab Versus Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n1. Age 18 years or older at the index date.\n2. Established diagnosis of ulcerative colitis for at least 3 months, supported by compatible clinical, endoscopic, and histologic findings.\n3. Moderately to severely active ulcerative colitis at baseline, defined as a modified Mayo score of 4 to 9 and a Mayo endoscopic subscore of at least 2.\n4. Initiation of upadacitinib induction therapy during the predefined study period.\n5. For the combination-therapy group, initiation of vedolizumab concomitantly with upadacitinib at the index date.\n\nExclusion Criteria:\n\n1. Crohn's disease, inflammatory bowel disease unclassified, indeterminate colitis, or another form of non-ulcerative-colitis colitis.\n2. Previous colectomy or colectomy planned at the index date.\n3. Previous exposure to upadacitinib or vedolizumab.\n4. Initiation of another biologic or small-molecule advanced therapy during the 8-week induction period, except for vedolizumab in the combination-therapy group.","ALL","18 Years",{"count":121,"type":122},150,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective comparative cohort study evaluated the real-world effectiveness and safety of upadacitinib plus vedolizumab compared with upadacitinib monotherapy during 8-week induction in adults with moderate-to-severe ulcerative colitis.\n\nConsecutive eligible patients who initiated upadacitinib induction therapy, either as monotherapy or with concomitant vedolizumab, between January 2023 and September 2025 at six tertiary inflammatory bowel disease referral centers in China were included.\n\nThe primary outcome was modified Mayo clinical remission at week 8. Secondary outcomes were modified Mayo clinical response, C-reactive protein normalization among patients with an elevated baseline C-reactive protein concentration, and endoscopic remission. Safety outcomes were assessed from the index date through the week-8 assessment.",[126],"Ulcerative Colitis (UC)",[128,22,26,129,130],"Ulcerative Colitis","Combination Therapy","Real-World Study","2026-07-29",{"date":133,"type":134},"2026-07-31","ACTUAL",{"date":136,"type":134},"2023-01-01",{"date":138,"type":122},"2026-09-01",{"name":5,"class":6},6]